[在高级NSCLC中免疫治疗的持久益处:呼吸队列]
S Deslais1, C Pierre2, T Goter2
1Service de pneumologie, CHU Pontchaillou, Rennes, France; Département de médecine générale, Université de Rennes 1, Rennes, France.
Revue des maladies respiratoires
|April 16, 2025
概括
晚期非小细胞肺癌 (NSCLC) 的长期存活可以通过免疫疗法实现. 一年多控制疾病的患者表现出非凡的无进展生存率和整体生存率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 非小细胞肺癌 (NSCLC) 研究的研究.
背景情况:
- 免疫检查点抑制剂已经改变了高级非小细胞肺癌 (NSCLC) 治疗.
- 显著的少数人 (8-16%) 实现长期生存,但这个群体研究不足.
研究的目的:
- 为了表征晚期NSCLC患者,通过免疫疗法实现持久的疾病控制 (≥12个月).
- 在这个队列中确定与长期无进展生存 (PFS) 和整体生存 (OS) 相关的因素.
主要方法:
- 转移性或局部晚期NSCLC患者的回顾性观察性研究 (BREATH).
- 纳入标准:免疫疗法治疗和疾病控制至少12个月后开始.
- 收集关于患者特征和治疗结果的数据.
主要成果:
- 平均51个月的随访后,没有达到PFS和OS的中位数.
- 36个月的PFS为64.7%,36个月的OS为91.6%.
- 完整的免疫治疗方案 (2年) 和基线白蛋白≥35g/L与改善PFS有关.
结论:
- 晚期NSCLC患者通过免疫疗法实现长时间的疾病控制,经历了异常的生存率.
- 这些发现表明,对于先进的NSCLC,治疗模式可能会发生转变.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.